Viventia to Present at Recombinant Antibodies Conference
03.06.2005 / 17:03 / Rubriek: Informatief / Organisatie: Viventia biotech
Viventia to Present at Recombinant Antibodies Conference
TORONTO, Canada, June 3/PRNewswire/ --
Viventia Biotech Inc. (TSX: VBI) today announced that Dr. Nick Glover, President and CEO will be presenting at Recombinant Antibodies, the leading European-based platform for sharing current antibody research.
When: Friday, June 3rd 2005 at 3:50 pm CET
Where: Hilton Berlin, Germany
What: Proxinium(TM) - A Novel Armed Antibody(TM) for the Treatment of Head and Neck Cancer: Initial Clinical Safety and Efficacy Results
About Viventia Biotech:
Viventia Biotech Inc. (TSX: VBI) is a biopharmaceutical company developing Armed Antibodies(TM), powerful and precise anti-cancer drugs designed to overcome various forms of cancer. Viventia's lead product is Proxinium(TM), which combines a cytotoxic protein payload significantly more powerful than traditional chemotherapies with the highly precise tumour-targeting characteristics of a monoclonal antibody. Proxinium(TM) is in clinical development for the treatment of head and neck cancer and bladder cancer, and is expected to enter advanced clinical trials in 2005.
This press release contains forward-looking statements, which are subject to risks and uncertainties inherent to the process of developing and commercialising human therapeutic products. Actual results could differ materially from those projected in this release. Certain statements included in this press release constitute forward looking statements. When used in this press release, the words 'anticipate', 'believe', 'plan', 'estimate', 'expect', 'intend', 'will', 'may', 'should' and similar expressions, as they relate to us or our management, are intended to identify forward-looking statements. These forward-looking statements are not historical facts but reflect our current expectations concerning future results and events. These statements include, without limitation, statements with respect to the clinical and developmental timelines associated with Proxinium.
The Toronto Stock Exchange has neither approved nor disapproved the information contained herein.
Source: Viventia Biotech Inc.
James Smith, Tel. +1-416-815-0700 x 229, Fax. +1-416-815-0080, Email: jsmith@viventia.com